drugset / Press release
Emergent BioSolutions Presents Preclinical Efficacy Data on ES414 Its Lead ADAPTIR Bispecific Therapeutic for Prostate Cancer
2013-05-03 · Emergent BioSolutions · original emergentbiosolutions.com ↗
050313 - ES414 Tolerability in CRPC at PEGS FINAL.pdf 212.4 KB
The release as fetched from its publisher. emergentbiosolutions.com ↗